Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.
复制标题
DOI：
10.1016/j.addr.2013.11.009
复制
发表时间：
2014-02
影响因子：
16.1
通讯作者：
Farokhzad, Omid C.
中科院分区：
文献类型：
--
作者：
Bertrand, Nicolas;Wu, Jun;Xu, Xiaoyang;Kamaly, Nazila;Farokhzad, Omid C.
关键词：
癌症纳米疗法正在稳步发展；自2000年初以来，该领域的研究和开发经历了指数级的增长。肿瘤药物的商业化道路很长，存在巨大的风险；然而，纳米技术可能有助于抗癌药物开发的成功，这一点令人相当兴奋。制药公司结成合作伙伴关系，使用专利纳米颗粒技术的速度大大加快。现在人们认识到，通过提高新药候选药物的疗效和/或耐受性，纳米技术可以对创造差异化产品和改善临床结果做出有意义的贡献。本综述描述了自包括Doxil®和Abraxane®在内的第一代纳米药物商业化以来的经验教训。它探索了我们目前对处于不同开发阶段的靶向和非靶向纳米颗粒的理解，包括BIND-014和MM-398。它强调了纳米医学在当代肿瘤学中面临的机遇和挑战，个性化医学日益成为癌症治疗的支柱。我们回顾了增强渗透性和滞留效应(EPR)的基本概念，并探索了无论是使用纳米颗粒的主动靶向、药物与其肿瘤靶点的结合还是肿瘤相关巨噬细胞的存在，都被认为可以增强肿瘤中的优先“滞留”的机制。这篇综述的总体目标是增进我们对治疗癌症的治疗纳米粒的设计和开发的理解。
Cancer nanotherapeutics are progressing at a steady rate; research and development in the field has experienced an exponential growth since early 2000’s. The path to the commercialization of oncology drugs is long and carries significant risk; however, there is considerable excitement that nanoparticle technologies may contribute to the success of cancer drug development. The pace at which pharmaceutical companies have formed partnerships to use proprietary nanoparticle technologies has considerably accelerated. It is now recognized that by enhancing the efficacy and/or tolerability of new drug candidates, nanotechnology can meaningfully contribute to create differentiated products and improve clinical outcome. This review describes the lessons learned since the commercialization of the first-generation nanomedicines including DOXIL® and Abraxane®. It explores our current understanding of targeted and non-targeted nanoparticles that are under various stages of development, including BIND-014 and MM-398. It highlights the opportunities and challenges faced by nanomedicines in contemporary oncology, where personalized medicine is increasingly the mainstay of cancer therapy. We revisit the fundamental concepts of enhanced permeability and retention effect (EPR) and explore the mechanisms proposed to enhance preferential “retention” in the tumor, whether using active targeting of nanoparticles, binding of drugs to their tumoral targets or the presence of tumor associated macrophages. The overall objective of this review is to enhance our understanding in the design and development of therapeutic nanoparticles for treatment of cancers.
登录
查看更多内容
影响因子：
4.9
作者：
Alexis F;Pridgen E;Molnar LK;Farokhzad OC
通讯作者：
Farokhzad OC
影响因子：
3.7
作者：
André, S;Frisch, B;Gabius, HJ
通讯作者：
Gabius, HJ
影响因子：
82.9
作者：
Alexandrakis, G;Brown, EB;Jain, RK
通讯作者：
Jain, RK
影响因子：
4.7
作者：
Ansell, SM;Tardi, PG;Buchkowsky, SS
通讯作者：
Buchkowsky, SS
DOI：
10.1039/9781849737821-00483
发表时间：
2013-01-01
期刊：
SUPRAMOLECULAR SYSTEMS IN BIOMEDICAL FIELDS
影响因子：
--
作者：
Bertrand, Nicolas;Colin, Patrick;Leblond, Jeanne
通讯作者：
Leblond, Jeanne